| symbol | subject | date & time | rating |
|
|
Interesting, Boehringer Ingelheim and Eli Lilly are rolling out an education campaign targeted at doctors and health care providers for their own SGLT2 inhibitor that may be rolling out soon. I think any push for SGLT2 in general will help once S... |
5/9/2013 8:13:46 PM |
|
|
|
Thanks again, nice advice there, both about this trade and trading in general, just so hard to stay emotionles sometimes. Just did re-read the press release and you definitely sound correct about the .84 affecting number of shares I can buy. Funn... |
5/8/2013 1:47:44 PM |
4 |
|
|
Thanks for the counter view supersceptic. I was just calculating it out and since I originally bought just a small amount at 0.62, buying more at .20 might not be the best bet. Especially since I just read the press release that makes it sound li... |
5/6/2013 11:11:30 AM |
1 |
|
|
That makes sense, thank you very much Vanhope, truly appreciate it! |
5/6/2013 10:03:00 AM |
1 |
|
|
Just noticed this as well. I am totally new to the stock game and never have received or executed rights before. What kind of play could be made with this? Advice is extremely appreciated! |
5/3/2013 1:24:56 PM |
1 |
|
|
Confuses me so much. Even Dundee has a buy rating with a $2.80 target Hoping tomorrow's Financial/Operating update will get this stock back on track. |
3/11/2013 11:25:20 AM |
|
|
|
Hey Guys, I'm a strong SBM supporter. Just wondering if anyone knows what happened around January 2011 though. On Jan 11, 2011 they hit a high of 0.84, then went lower in February and just went on a slow crawl from there, Looks like a big spi... |
3/1/2013 2:25:10 PM |
|
|
|
Hey robvanhooren, I get these same emails which made me start looking at COA the other day. I actually am a loyal customer, and fan, of Clearly Contacts up here in Canada, one of COA's companies. For a few years I've been loving them and ... |
2/26/2013 9:57:23 AM |
|
|
|
Just received this news release: "February 22, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF, Frankfurt: ZSB), announced today a non-brokered private placement of up to 27,000,000 units of the Company at a price of US$0.10 per ... |
2/22/2013 12:32:36 PM |
|
|
|
Just an article from a Google Alert. SBM has an SGLT2 inhibitor for type2 diabetes that was proven to be more effective than Johnson and Johnsons canagliflozin, which might be called Invokana. Don't think the article means anything for SBM, b... |
2/7/2013 12:02:00 AM |
4 |
|
No additional content to display.
Stockhouse.com: Taking
it to the street
